<DOC>
	<DOCNO>NCT02730390</DOCNO>
	<brief_summary>The primary objective post marketing surveillance ( PMS ) determine safety efficacy probucol lower level serum cholesterol blood .</brief_summary>
	<brief_title>Study Efficacy Safety Oral Probucol Tablets Patients With Hyperlipidemia - Post-Marketing Surveillance</brief_title>
	<detailed_description>This nationwide post marketing surveillance target recruit total 3,000 patient hyperlipidemia . Duration treatment 60 day . The usual starting dose Lorelco 500 mg administer daily , divide two ( 2 ) dos ( 250mg BID ) give meal . The dose may adjust accord patient 's age condition . Lipid serum test obtain Day 0 ( Baseline ) . In subject require antihyperlipidemics fulfill inclusion criterion , Lorelco 250 BID start . There 2 follow-up visit baseline Day 30 Day 60 . Both lipid serum test ECG do 2 follow-up visit . During visit investigator ass subject 's vital sign symptom check adverse event . The primary outcome measure percentage reduction increase total cholesterol triglyceride baseline value Week 0 Week 4 Week 8 use follow scale : Total Cholesterol Triglycerides 1 . Markedly reduce 2 . Moderately reduce 3 . Slightly reduce 4 . Unchanged 5 . Increased Reduction ≥ 15 % Reduction ≥ 10 % &lt; 15 % Reduction ≥ 5 % &lt; 10 % Change &lt; 5 % Increase ≥ 5 % Reduction ≥ 30 % Reduction ≥ 20 % &lt; 30 % Reduction ≥ 10 % &lt; 20 % Change &lt; 10 % Increase ≥ 10 % The percentage change last week treatment final evaluation . The secondary outcome measure change symptom vital sign . Using follow scale : 1 . Markedly Improved 2 . Improved 3 . Slightly Improved 4 . Unchanged 5 . Aggravated 6 . Unknown ( assessable ) Safety measure incidence adverse event collect . Overall efficacy safety evaluate assess usefulness Lorelco use follow scale : 1 . Very useful 2 . Useful 3 . Somewhat useful 4 . Not useful 5 . Unfavorable 6 . Unknown ( assessable )</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Diagnosed hyperlipidemia include familial hypercholesterolemia xanthoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>